WuXi Biologics WKN: A2QJCN ISIN: KYG970081173 Forum: Aktien User: Summer.76

Gerne! Mehr weiß ich momentan leider auch nicht.

Danke Summer.76

Habe leider auch nur die 'örtlichen' News gefunden und die Übersetzung liest sich, als wenn man es am Kurs dann ab morgen merken dürfte - scheint nachbörslich veröffentlicht worden zu sein. Im letzten Jahr hatte die Holding 4x im größeren Umfang die Beteiligung an WuXi reduziert. Lag zuletzt noch bei gut 23 % (Anfang September). Kannst ja mal den link von Anfang September 20 durch den Übersetzer jagen: https://hk.appledaily.com/finance/20200902/MGTRSFF5KZAEFJAXB52C3WUROI/ Ich habe es jetzt aber nicht auf dem Schirm, ob sie dann noch Hauptaktionär bleiben.

Danke Summer.76 für die Inhalte - sehr hilfreich. Habe auch recherchiert und das Unternehmen investiert strategisch gut. Will nun mit einiger 5.000€ Position rein. Wie sieht es in Hong Kong aus? Die letzte Nachricht hat mich stutzig gemacht, ist die eher positiv odernegativ zu bewerten?

Wuxi Biologics controlling shareholder reps up to HK$7.9m in share placement https://www.thestandard.com.hk/breaking-news/section/1/162551/Wuxi-Biologics-controlling-shareholder-reps-up-to-HK$7.9m-in-share-placement

Noch ein weiterer Beitrag bzgl der Meldung von 12:28 Uhr. Scheint nachbörslich gekommen zu sein und dürfte sich dann ab morgen entsprechend auf den Kurs auswirken, wenn ich es richtig verstehe. WuXi Biologics (02269) major shareholder reduces holdings and cashes out up to nearly 8 billion yuan http://www.aimpact.com/article/zho/%E8%97%A5%E6%98%8E%E7%94%9F%E7%89%A9-02269-%E5%A4%A7%E8%82%A1%E6%9D%B1%E5%86%8D%E6%B8%9B%E6%8C%81%E5%A5%97%E7%8F%BE%E6%9C%80%E5%A4%9A%E8%BF%9180%E5%84%84%E5%85%83-4243145165 Foreign Telecom quoted a sales document to disclose that WuXi Biologics, the major shareholder of WuXi Biologics (02269), once again reduced its holdings, placing 82 million shares at 95-97 yuan per share, and cashing out 7.79-7.954 billion yuan. 

WuXi to make COVID-19 vaccine at shelved Bayer hemophilia drug plant https://bioprocessintl.com/bioprocess-insider/facilities-capacity/wuxi-to-make-covid-19-vaccine-at-shelved-bayer-hemophilia-drug-plant/

WuXi Biologics major shareholder rumored to reduce holdings and cash out over 7.7 billion https://www2.hkej.com/landing/mobArticle2/id/2677426 The foreign news agency quoted the sale document to disclose that WuXi Biologics, the major shareholder of WuXi Biologics ( 02269 ), placed 82 million shares at RMB 95 to RMB 97 per share, realizing 7.79 billion to 7.954 billion. The price per share is 103.2 yuan from today's closing price, a discount of 6.01% to 7.95%.

Es freut mich, wenn die Infos hilfreich sind. Danke dir und auch ich wünsche ein frohes, gesundes und erfolgreiches neues Jahr 🍀🍀🍀

... die Infos sind toll!

Danke Summer für die ganzen bereitgestellten Infos und Links! Wünsche ein gesundes und erfolgreiches 2021!

Ein sehr schöner Jahresabschluss meines Erachtens! Guten Rutsch allerseits 🍀🥂🍀

http://www.aastocks.com/en/stocks/analysis/stock-aafn-con/02269/NOW.1066316/hk-stock-news Top 5 Strongest, Weakest HSI Constituents in 2020 (Table)

The Hang Seng Index fell more than 3% throughout the year, WuXi Biologics rose 212.6% throughout the year, the strongest blue chip http://www.hkcd.com/content/2020-12/31/content_1239826.html Hong Kong stocks regained the level of 27,000 points at the end of the year, and the Hang Seng Index rose 84 points on New Year's Eve to close at 27,231 points, a cumulative decline of 958 points or 3.4% throughout the year. Among the constituent stocks of the Hang Seng Index, pharmaceutical stocks continued to become the blue-chip gainers this year. After Zhongsheng Pharmaceutical (01177) was the blue-chip gainer last year, WuXi Biologics (02269) relayed this year and among the constituent stocks of the Hang Seng Index, the blue chip stocks performed the best. WuXi Biologics (02269) rose nearly 3.5% today, and broke the top and closed the market with a daily high of RMB 102.8, becoming a "red stock". WuXi Biologics has gained 212.6% for the year, making the blue chip king.

WuXi Biologics' leading position is firmly established http://www.aastocks.com/tc/stocks/news/comment.aspx?id=27996 ... The adjustment of the mainland medical insurance catalogue was announced a few days ago, and the average price of medicines is reduced by about 51%. The decline of related drugs is smaller than market expectations, and the support sector has recently resumed its upward trend. Among them, WuXi Biologics (02269.HK) has repeatedly set new highs, and it should not be difficult to break the "red reserve price" of 100 yuan. The company's business mainly provides biologics drug discovery, development and production services. The CRO market in which it is located has been a hot market in recent years , The company is the absolute leader in the field of biopharmaceutical CRO in the Mainland, with a market share approaching 80%. Benefited from the global demand for innovative drug research and development coupled with the stimulus of the epidemic, the business has grown rapidly and its position has been stable. Note absorption. Credit Suisse issued a research report stating that WuXi’s stock price has performed strongly recently. Credit Suisse believes that it may be due to the improved atmosphere of the new round of negotiations on the National Medical Insurance Drug Catalog, which has driven the entire sector to rise. Taking into account the adjustment of short-term earnings forecasts, it will earn per share this year The forecast is revised down by 1.3%, and the earnings per share estimates for 2021-2022 are revised up by 5.3% and 4.6%. The target price is raised from RMB 86.67 to RMB 107. The “Outperform” rating is maintained. It is believed that the demand for R&D outsourcing business is strong. ...

Applications and Impact of CRISPR/CAS9 in Bioprocessing https://cellculturedish.com/applications-and-impact-of-crispr-cas9-in-bioprocessing/ In this podcast, we conducted a panel discussion with experts from WuXi Biologics about one of the great technology advancements of the last decade, CRISPR/Cas9 technology.  We discussed the technology’s potential and in particular its possibilities in the discovery and development of biopharmaceuticals. We also conducted a deep dive on its potential impact on bioprocessing and biomanufacturing.